Full Text View
Tabular View
No Study Results Posted
Related Studies
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
This study is currently recruiting participants.
Verified January 2013 by Comprehensive Cancer Center of Wake Forest University
Study NCT00601913   Information provided by Comprehensive Cancer Center of Wake Forest University

First Received on January 24, 2008.   Last Updated on January 25, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck Cancer
Additional conditions recognized in this trial
Carcinoma, Squamous Cell
Head and Neck Neoplasms
More general conditions related to this trial
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
erlotinib hydrochloride
protein analysis
western blotting
laboratory biomarker analysis
liquid chromatography
mass spectrometry
neoadjuvant therapy
therapeutic conventional surgery
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
Comprehensive Cancer Center of Wake Forest University
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services